Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

rVWF IN PROPHYLAXIS

Phase 3

Completed

Conditions: Von Willebrand Disease

Interventions: Biological: von Willebrand factor (Recombinant)
Biological: Antihemophilic Factor (Recombinant)

First Posted Date: 2016-11-25

Last Posted Date: 2021-08-06

Lead Sponsor: Takeda

Target Recruit Count: 29

Registration Number: NCT02973087

Locations: 🇫🇷
Hôpital Morvan, Brest, Finistere, France
🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇫🇷
CHU Dijon - Hopital du Bocage, Dijon cedex, France

and more 28 locations

Goal Achievement After a Change to Vortioxetine in Adults With Major Depressive Disorder

Phase 4

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Vortioxetine

First Posted Date: 2016-11-23

Last Posted Date: 2019-07-11

Lead Sponsor: Takeda

Target Recruit Count: 123

Registration Number: NCT02972632

Locations: 🇺🇸
University of Michigan, Ann Arbor, Ann Arbor, Michigan, United States
🇺🇸
Novex Clinical Research, LLC, New Bedford, Massachusetts, United States
🇺🇸
University of South Florida, Tampa, Florida, United States

and more 22 locations

An Efficacy and Safety Study Evaluating the Fixed-Dose Combination of Candesartan Plus Amlodipine in Participants With Mild/Moderate Essential Hypertension

Phase 3

Withdrawn

Conditions: Hypertension

Interventions: Drug: Amlodipine
Drug: TCV-116CCB
Drug: Amlodipine Placebo
Drug: TCV-116CCB Placebo

First Posted Date: 2016-11-21

Last Posted Date: 2017-06-09

Lead Sponsor: Takeda

Registration Number: NCT02969265

Locations: 🇨🇳
The Xiangya Hospitalof Central South University, Changsha, Hunan, China
🇨🇳
People's Hospital of Wuhan University, Wuhan, Hubei, China
🇨🇳
Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

and more 22 locations

Cohort Study of Pioglitazone and Cancer Incidence in Participants With Diabetes Mellitus.

Completed

Conditions: Diabetes Mellitus, Type 2, Cancer

Interventions: Drug: Pioglitazone

First Posted Date: 2016-11-08

Last Posted Date: 2018-03-07

Lead Sponsor: Takeda

Target Recruit Count: 236507

Registration Number: NCT02958956

Epidemiologic Study Of Diabetes And Cancer Risk

Completed

Conditions: Diabetes Mellitus, Type 2, Cancer

Interventions: Other: No Intervention

First Posted Date: 2016-11-08

Last Posted Date: 2018-03-07

Lead Sponsor: Takeda

Target Recruit Count: 2738161

Registration Number: NCT02958995

Phase 3 Study of TAK-438 10 mg in the Treatment of Non-Erosive Gastroesophageal Reflux Disease (NERD)

Phase 3

Completed

Conditions: Non-erosive Gastroesophageal Reflux Disease

Interventions: Drug: Placebo
Drug: TAK-438 10 mg

First Posted Date: 2016-11-04

Last Posted Date: 2019-08-02

Lead Sponsor: Takeda

Target Recruit Count: 484

Registration Number: NCT02954848

Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children

Phase 2

Completed

Conditions: Healthy Volunteers

Interventions: Biological: TDV

First Posted Date: 2016-10-28

Last Posted Date: 2024-03-15

Lead Sponsor: Takeda

Target Recruit Count: 200

Registration Number: NCT02948829

Locations: 🇵🇭
Research Institute for Tropical Medicine, Muntinlupa, Philippines
🇵🇦
CEVAXIN, Panama, Panama

Brentuximab Vedotin in Chinese Participants With Relapsed/Refractory CD30-Positive Hodgkin Lymphoma (HL) or Systemic Anaplastic Large Cell Lymphoma (sALCL)

Phase 2

Completed

Conditions: Hodgkin Disease
Lymphoma, Large-Cell, Anaplastic

Interventions: Drug: Brentuximab Vedotin

First Posted Date: 2016-10-19

Last Posted Date: 2021-02-24

Lead Sponsor: Takeda

Target Recruit Count: 39

Registration Number: NCT02939014

Locations: 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳
Sun Yat-san University Cancer Center, Guangzhou, Guangdong, China

and more 4 locations

Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning in Healthy Volunteers

Phase 4

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Vortioxetine
Drug: Paroxetine
Drug: Placebo

First Posted Date: 2016-10-13

Last Posted Date: 2018-09-14

Lead Sponsor: Takeda

Target Recruit Count: 361

Registration Number: NCT02932904

Ixazomib Rollover Study

Phase 2

Completed

Conditions: Multiple Myeloma
Lymphoma
Amyloidosis

Interventions: Drug: Ixazomib

First Posted Date: 2016-10-05

Last Posted Date: 2024-08-05

Lead Sponsor: Takeda

Target Recruit Count: 31

Registration Number: NCT02924272

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇨🇦
University Health Network, Toronto, Ontario, Canada
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada

and more 23 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy